Exploiting Common Genetic Variation to Make Anticoagulation Safer

被引：15

作者：

Chang, Yuchiao ^{[1
]}

Cortellini, Lynelle ^{[1
]}

Greenberg, Steven M. ^{[1
]}

Rosand, Jonathan ^{[1
]}

Singer, Daniel ^{[1
]}

Schwab, Kristen ^{[1
]}

Selim, Magdy ^{[2
]}

Meschia, James ^{[3
]}

Eckman, Mark H. ^{[4
]}

Silliman, Scott ^{[5
]}

Brown, Devon ^{[6
]}

Worrall, W. Bradford ^{[7
]}

Tirschwell, David ^{[8
]}

Gage, Brian F. ^{[9
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Mayo Clin, Jacksonville, FL 32224 USA

[4] Univ Cincinnati, Cincinnati, OH 45221 USA

[5] Univ Florida, Gainesville, FL 32611 USA

[6] Univ Michigan, Ann Arbor, MI 48109 USA

[7] Univ Virginia, Charlottesville, VA 22903 USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Washington Univ, St Louis, MO 63130 USA

来源：

STROKE | 2009年 / 40卷 / 03期

关键词：

anticoagulation; ATRIAL-FIBRILLATION; CYTOCHROME P450CYP2C9-ASTERISK-2; CYP2C9-ASTERISK-3; ALLELES; HEMORRHAGIC COMPLICATIONS; INTRACEREBRAL HEMORRHAGE; BLEEDING COMPLICATIONS; WARFARIN THERAPY; RISK; CYP2C9; POLYMORPHISMS;

D O I：

10.1161/STROKEAHA.108.533190

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S64 / S66

页数：3

共 18 条

[1]

Adcock DM, 2004, ARCH PATHOL LAB MED, V128, P1360

[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[3] Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation How Will Screening With Genetics and Imaging Help? [J].

Eckman, Mark H. ;

Wong, Lawrence K. S. ;

Soo, Yannie O. Y. ;

Lam, Wynnie ;

Yang, Song Ran ;

Greenberg, Steven M. ;

Rosand, Jonathan .

STROKE, 2008, 39 (12) :3308-3315

[4] Death and disability from warfarin-associated intracranial and extracranial hemorrhages [J].

Fang, Margaret C. ;

Go, Alan S. ;

Chang, Yuchiao ;

Hylek, Elaine M. ;

Henault, Lori E. ;

Jensvold, Nancy G. ;

Singer, Daniel E. .

AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :700-705

[5] Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study [J].

Fang, Margaret C. ;

Go, Alan S. ;

Hylek, Elaine M. ;

Chang, Yuchiao ;

Henault, Lori E. ;

Jensvold, Nancy G. ;

Singer, Daniel E. .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (08) :1231-1236

[6] Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation [J].

Fang, MC ;

Chang, YC ;

Hylek, EM ;

Rosand, J ;

Greenberg, SM ;

Go, AS ;

Singer, DE .

ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) :745-752

[7] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].

Higashi, MK ;

Veenstra, DL ;

Kondo, LML ;

Wittkowsky, AK ;

Srinouanprachanh, SL ;

Farin, FM ;

Rettie, AE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698

[8] Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin [J].

Limdi, Na ;

McGwin, G. ;

Goldstein, J. A. ;

Beasley, T. M. ;

Arnett, D. K. ;

Adler, B. K. ;

Baird, M. F. ;

Acton, R. T. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :312-321

[9]

Margaglione M, 2000, THROMB HAEMOSTASIS, V84, P775

[10] The effect of warfarin and intensity of anticoagulation on outcome of intracerebral Hemorrhage [J].

Rosand, J ;

Eckman, MH ;

Knudsen, KA ;

Singer, DE ;

Greenberg, SM .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (08) :880-884

← 1 2 →